Intravenous Immunoglobulin in Treating Nonventilated COVID-19 Patients With Moderate-to-Severe Hypoxia: A Pharmacoeconomic Analysis
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
No abstract available
Article activity feed
-
-
SciScore for 10.1101/2021.09.26.21264152: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: This analysis received approval from the health system’s Institutional Review Board (IRB), and was granted a waiver of subject authorization given the retrospective nature of the study. Sex as a biological variable not detected. Randomization Patient Cohort #2-Prospective Randomized Trial: IVIG (Octagam 10%, Octapharma, Inc) use in COVID-19 was studied in a previously published prospective open-label randomized trial. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Outcomes: Cost data was independently obtained from our finance team who provided us with the total direct cost and the total pharmaceutical cost associated with each … SciScore for 10.1101/2021.09.26.21264152: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics IRB: This analysis received approval from the health system’s Institutional Review Board (IRB), and was granted a waiver of subject authorization given the retrospective nature of the study. Sex as a biological variable not detected. Randomization Patient Cohort #2-Prospective Randomized Trial: IVIG (Octagam 10%, Octapharma, Inc) use in COVID-19 was studied in a previously published prospective open-label randomized trial. Blinding not detected. Power Analysis not detected. Table 2: Resources
Software and Algorithms Sentences Resources Outcomes: Cost data was independently obtained from our finance team who provided us with the total direct cost and the total pharmaceutical cost associated with each admission. Costsuggested: (COST, RRID:SCR_014098)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:The major limitations of this study include the small sample size and the potential lack of generalizability of these results to all hospital centers. Our group has generated considerable experience in IVIG utilization in COVID-19 and as a result, has identified a ‘sweet spot’ where benefit was seen clinically and economically. However, it remains to be determined if IVIG will benefit patients with greater illness severity such as those in the ICU, on mechanical ventilation, or ECMO. Furthermore, while a significant morbidity and mortality burden of COVID-19 rests in extremely elderly patients and those with end-organ comorbidities such as renal failure and heart failure, it is uncertain if their COVID-19 adverse outcomes can be improved with IVIG or other therapies. We believe such patients may limit the pharmacoeconomic value of IVIG due to their generally poorer prognosis regardless of intervention. On the other hand, COVID-19 patients who are not that severely ill with minimal to no hypoxia generally will do well regardless of therapy and IVIG intervention may be potentially be an unnecessary treatment expense. Evidence for this was hinted in our pilot trial10 and supported in a recent meta-analysis of IVIG therapy in COVID-19.16 Several other therapeutic options with high acquisition costs have seen an increase in use during the COVID-19 pandemic despite relatively lukewarm data. Remdesivir, the first drug found to have a beneficial effect on hospitalized patients with C...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-
